Algeta ASA : Algeta celebrates the official opening of its commercial production facility for Xofigo® (radium Ra 223 dichloride

    Algeta ASA : Algeta celebrates the official opening of its commercial
 production facility for Xofigo® (radium Ra 223 dichloride) at the Institute
                    for Energy Technology (IFE) in Norway

Not intended for US media

Oslo, Norway, 20 June 2013  - Algeta ASA (OSE:  ALGETA), a company focused  on 
the development of  novel targeted cancer  therapeutics, today celebrates  the 
official opening of its commercial production facility for Xofigo^® (radium Ra
223 dichloride)  at the  Institute  for Energy  Technology (IFE)  in  Kjeller, 

Andrew Kay, Algeta's President & CEO, and senior management colleagues will be
joined by Trond Giske, the Norwegian  Minister for Trade and Industry, Eva  S. 
Dugstad, President of IFE and Andreas Fibig, President & Chairman of the Board
of Management,  Bayer  HealthCare  Pharmaceuticals,  and  other  distinguished 
guests for an official ribbon cutting ceremony this afternoon.

Xofigo was approved by the US Food and Drug Administration (FDA) on 15 May for
the treatment of  patients with castration-resistant  prostate cancer  (CRPC), 
symptomatic bone metastases and  no known visceral  metastatic disease. It  is 
the first alpha  particle-emitting radioactive therapeutic  agent approved  by 
the FDA. Algeta US, LLC and  Bayer Healthcare are co-promoting the product  in 
the US.  Xofigo has  been launched  in the  US, triggering  a EUR  50  million 
milestone payment to Algeta from Bayer. Bayer Healthcare has licensed the full
rights to Xofigo outside of the US.

Radium Ra  223  dichloride (radium  223)  is  currently not  approved  by  the 
European Medicines Agency  (EMA) or  other authorities outside  the US.  Bayer 
submitted a Marketing Authorisation Application to  the EMA for radium 223  in 
December 2012 for the treatment of CRPC patients with bone metastases.

Andrew Kay, Algeta's President & CEO, said: "The recent approval and launch of
Xofigo in the US are  momentous achievements for Algeta  and put us firmly  on 
the path to deliver on our  vision of becoming a world-class oncology  company 
bringing novel targeted medicines to cancer patients through our leadership in
alpha particle-emitting pharmaceuticals. IFE has been an important partner  to 
Algeta throughout the  clinical development  of radium  223, and  it has  been 
instrumental in  helping us  build a  commercial production  facility for  the 
global supply of  Xofigo. We  are all  extremely grateful  for the  expertise, 
dedication and support  that IFE has  provided to Algeta  on this journey  and 
look forward to continuing our productive partnership."

"Today's opening of a new commercial production facility at IFE underlines the
Norwegian  pharmaceutical  industry's   ability  to   develop  products   with 
significant global potential.We are proud to have played an integral part  in 
the  development  of  Xofigo   that  has  required  state-of-the-art   quality 
manufacturing throughout its path to market.  The new facility which is  being 
officially opened  today  has  been  designed  according  to  highest  quality 
standards - from raw material handling to the release of the final  commercial 
product," said Eva S. Dugstad, President of the IFE.

"On behalf of Bayer, I am proud  and excited to be part of this  collaboration 
with our Norwegian partners, Algeta and IFE," said Andreas Fibig, Head of  the 
Pharmaceuticals Division of Bayer. "Now is the time for the patients to  gain 
from it. Our hope is that Xofigo can help patients with bone metastases caused
by prostate cancer all over the world. There is a great need for new treatment
options for these patients, and our clinical studies show that Xofigo can help
patients to live longer. For me, representing a pharma company having 'Science
for a better life' as its mission,  it is deeply gratifying to know that  what 
will be produced here will improve many peoples' lives."

About Xofigo^® (radium Ra 223 dichloride)

Xofigo is indicated  for the treatment  of patients with  castration-resistant 
prostate cancer, symptomatic bone metastases and no known visceral  metastatic 

Xofigo is an  alpha particle-emitting  radioactive therapeutic  agent with  an 
anti-tumor effect on bone metastases. The  active ingredient in Xofigo is  the 
alpha particle-emitting  isotope radium-223,  which mimics  calcium and  forms 
complexes with  the bone  mineral hydroxyapatite  at areas  of increased  bone 
turnover, such  as  bone  metastases.  The  high  linear  energy  transfer  of 
radium-223 may cause double-strand DNA breaks in adjacent cells, resulting  in 
an anti-tumor  effect  on  bone  metastases. The  alpha  particle  range  from 
radium-223 is less  than 100  micrometers which may  limit the  damage to  the 
surrounding normal tissue^[i].

In September 2009, Algeta signed an  agreement with Bayer for the  development 
and commercialization of Xofigo. Under the terms of the agreement, Bayer  will 
develop, apply  for health  authority  approvals worldwide  and  commercialize 
Xofigo globally. Algeta US, LLC is co-promoting Xofigo with Bayer in the US.

For full prescribing information visit 


Xofigo^® is a registered trademark of Bayer

For further information, please contact:

Mike Booth / Renate Birkeli        +47 23 00 67 32
Communications & Corporate Affairs
Media enquiries:
Mark Swallow                       +44 207 638 9571
Citigate Dewe Rogerson   
Knut Ekern                         +47 22 04 82 00
Gambit Hill & Knowlton   
US investor enquiries:
Tricia Swanson                     +1 646 378 2953
The Trout Group          

About Algeta

Algeta is  a  company  focused  on developing  novel  targeted  therapies  for 
patients with cancer based on  its alpha-pharmaceutical platform. The  Company 
is headquartered in  Oslo, Norway, and  has a US  subsidiary, Algeta US,  LLC, 
based in Cambridge, MA performing  commercial marketing operations in the  US. 
Algeta is  listed  on the  Oslo  Stock  Exchange (Ticker:  ALGETA).  For  more 
information please visit

Forward-looking Statements

This news release contains certain  forward-looking statements that are  based 
on uncertainty, as they relate to events and depend on circumstances that will
occur in the future and which, by their nature, may have an impact on  results 
of operations  and the  financial condition  of Algeta.  Such  forward-looking 
statements reflect  our  current  views  and  are  based  on  the  information 
currently available to Algeta. Algeta cannot give any assurance as to  whether 
such forward  looking  statements will  prove  to be  correct.  These  forward 
looking statements include statements regarding our co-promotion of Xofigo  in 
the US and our ability to manufacture radium 223 on a global scale. There  are 
a number of factors that could cause actual results and developments to differ
materially  from  those   expressed  or  implied   by  these   forward-looking 
statements. These factors include, among other things, risks or  uncertainties 
associated with  the ability  to  identify and  hire  a sufficient  number  of 
qualified employees  in  the  US,  growth  management,  general  economic  and 
business conditions and  the pricing environment,  the impact of  competition, 
the  ability  to  successfully  commercialize  Xofigo,  the  risk  that  costs 
associated with the co-promotion  of Xofigo may  be greater than  anticipated, 
manufacturing capacity, the risk of  non-approval of patents not yet  granted, 
risks in  obtaining additional  regulatory approvals  for radium  223 and  the 
other risks and uncertainties described in our annual report.

[i]XOFIGO Prescribing information. May 2013

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.